156 related articles for article (PubMed ID: 25437118)
1. The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
Liu J; Deng GH; Zhang J; Wang Y; Xia XY; Luo XM; Deng YT; He SS; Mao YY; Peng XC; Wei YQ; Jiang Y
Psychoneuroendocrinology; 2015 Feb; 52():130-42. PubMed ID: 25437118
[TBL] [Abstract][Full Text] [Related]
2. Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.
Deng GH; Liu J; Zhang J; Wang Y; Peng XC; Wei YQ; Jiang Y
J Exp Clin Cancer Res; 2014 Feb; 33(1):21. PubMed ID: 24555849
[TBL] [Abstract][Full Text] [Related]
3. Role of transforming growth factor-β1 pathway in angiogenesis induced by chronic stress in colorectal cancer.
Zhang J; Deng YT; Liu J; Gan L; Jiang Y
Cancer Biol Ther; 2024 Dec; 25(1):2366451. PubMed ID: 38857055
[TBL] [Abstract][Full Text] [Related]
4. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells.
Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
J Med Invest; 2017; 64(3.4):250-254. PubMed ID: 28954991
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Suddek GM
Cancer Chemother Pharmacol; 2011 May; 67(5):1035-44. PubMed ID: 20652569
[TBL] [Abstract][Full Text] [Related]
8. A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Pauty J; Usuba R; Cheng IG; Hespel L; Takahashi H; Kato K; Kobayashi M; Nakajima H; Lee E; Yger F; Soncin F; Matsunaga YT
EBioMedicine; 2018 Jan; 27():225-236. PubMed ID: 29289530
[TBL] [Abstract][Full Text] [Related]
9. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
[TBL] [Abstract][Full Text] [Related]
12. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
13. Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.
Faes S; Uldry E; Planche A; Santoro T; Pythoud C; Demartines N; Dormond O
Oncotarget; 2016 Dec; 7(52):86026-86038. PubMed ID: 27852069
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
[TBL] [Abstract][Full Text] [Related]
15. Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.
Torok S; Vegvari A; Rezeli M; Fehniger TE; Tovari J; Paku S; Laszlo V; Hegedus B; Rozsas A; Dome B; Marko-Varga G
Br J Pharmacol; 2015 Feb; 172(4):1148-63. PubMed ID: 25363319
[TBL] [Abstract][Full Text] [Related]
16. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.
Han KS; Li N; Raven PA; Fazli L; Frees S; Ettinger S; Park KC; Hong SJ; Gleave ME; So AI
Oncotarget; 2015 Oct; 6(33):34818-30. PubMed ID: 26472187
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
19. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
